About Presenilin-2
Presenilin-2 (PSEN2) is a protein
from Homo sapiens identified by UniProt accession
P49810, 448 residues long.
MolForge cross-references it against 0 known binders and
243 disease associations.
Target properties
| Protein name | Presenilin-2 |
|---|
| UniProt accession | P49810 |
|---|
| Gene | PSEN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 448 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (243)
Diseases linked to this target (Open Targets).
- early-onset autosomal dominant Alzheimer disease · score 0.68
- dilated cardiomyopathy 1V · score 0.48
- Dementia · score 0.45
- Alzheimer disease · score 0.42
- familial isolated dilated cardiomyopathy · score 0.37
- dementia · score 0.37
- heel bone mineral density · score 0.36
- Desmoid-type fibromatosis · score 0.29
- lymphocyte count · score 0.29
- Huntington disease-like syndrome · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P49810-F1 | alphafold | PREDICTED | 71.79 | — |
Amino-acid sequence (448 residues)
MLTFMASDSE EEVCDERTSL MSAESPTPRS CQEGRQGPED GENTAQWRSQ ENEEDGEEDP DRYVCSGVPG RPPGLEEELT LKYGAKHVIM LFVPVTLCMI VVVATIKSVR FYTEKNGQLI YTPFTEDTPS VGQRLLNSVL NTLIMISVIV VMTIFLVVLY KYRCYKFIHG WLIMSSLMLL FLFTYIYLGE VLKTYNVAMD YPTLLLTVWN FGAVGMVCIH WKGPLVLQQA YLIMISALMA LVFIKYLPEW SAWVILGAIS VYDLVAVLCP KGPLRMLVET AQERNEPIFP ALIYSSAMVW TVGMAKLDPS SQGALQLPYD PEMEEDSYDS FGEPSYPEVF EPPLTGYPGE ELEEEEERGV KLGLGDFIFY SVLVGKAAAT GSGDWNTTLA CFVAILIGLC LTLLLLAVFK KALPALPISI TFGLIFYFST DNLVRPFMDT LASHQLYI
Explore Presenilin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets